IL2 and neoplasm: The use of mesenchymal stem cells (MSCs) may be a potential strategy that can reduce systemic toxicity and ensure targeted delivery of IL2 as well as maintain high levels of IL2 in the tumor microenvironment, since MSCs have the ability to migrate toward tumor sites in vivo [13,14,15].